Sign In
Buy CGEN
$2.34
-0.0700 (-2.90%)
At Close: Aug 10, 2026
Compugen Reports First Quarter 2026 Results
07:00am, Monday, 18'th May 2026
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvegostomig acr
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
07:00am, Tuesday, 12'th May 2026
HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, to
Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
07:00am, Monday, 04'th May 2026
HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/M
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
07:00am, Thursday, 09'th Apr 2026
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen Q4 Earnings Call Highlights
01:34am, Wednesday, 04'th Mar 2026
Compugen (NASDAQ: CGEN) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight a strengthened balance sheet following a non-dilutive transaction with AstraZeneca, c
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement
02:35pm, Monday, 02'nd Mar 2026
Compugen remains a 'Buy,' supported by pipeline progress, major pharma partnerships, and a cash runway extended into 2029. Key catalysts include the phase 3 MAIA-Ovarian cancer trial (COM701), with in
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
11:17am, Monday, 02'nd Mar 2026
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
09:16am, Monday, 02'nd Mar 2026
Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago.
Compugen Reports Fourth Quarter and Full Year 2025 Results
07:00am, Monday, 02'nd Mar 2026
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leaders
Compugen to Participate in Upcoming Investor Conferences
07:00am, Thursday, 19'th Feb 2026
HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
07:00am, Tuesday, 17'th Feb 2026
HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
07:00am, Thursday, 12'th Feb 2026
HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
07:00am, Wednesday, 17'th Dec 2025
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
10:51am, Monday, 10'th Nov 2025
Compugen Ltd. ( CGEN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Yvonne Naughton - Head of Investor Relations & Corporate Communications Eran Ophir - CEO & Director Davi
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
09:16am, Monday, 10'th Nov 2025
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.01 per share a year ago.
